UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049847
Receipt number R000056782
Scientific Title Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma
Date of disclosure of the study information 2022/12/22
Last modified on 2023/09/28 10:11:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma

Acronym

Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma

Scientific Title

Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma

Scientific Title:Acronym

Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma

Region

Japan


Condition

Condition

Hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To clarify the well-being changes and those reasons in patients with hepatocellular carcinoma receiving repeated locoregional therapy (hepatectomy or ablation).

Basic objectives2

Others

Basic objectives -Others

To clarify the important things for patients in locoregional therapy and adjuvant therapy from the views of patients who received locoregional therapy and physicians who performed locoregional therapy, respectively.

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Well-being and the factors associated with well-being changes in patients with Early-stage hepatocellular carcinoma

Key secondary outcomes

To clarify the important things for patients in locoregional therapy and adjuvant therapy from the views of patients who received locoregional therapy and physicians who performed locoregional therapy, respectively.


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients
1. Aged less than 20years
2.Residents of Japan who received locoregional therapy for hepatocellular carcinoma (hepatectomy or ablation) more than two times
3.Within 5 years of last locoregional therapy (hepatectomy or ablation)
4.Signed informed consent form
Physicians
1.Licensed Japanese medical doctors who performed an average of at least 5cases/year of hepatectomy or ablation within 5 years
2.At least five cases of hepatectomy or ablation in the last year
3.Signed informed consent form

Key exclusion criteria

Patients who are engaged in a pharmaceutical, medical, or survey-related job

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Hiroki
Middle name
Last name Matsumoto

Organization

Ono Pharmaceutical Co., Ltd.

Division name

Oncology Medical, Medical Affairs

Zip code

103-0023

Address

9-11, Nihonbashi-Honcho 4-Chome Chuo-ku, Tokyo

TEL

03-5640-3711

Email

hi.matsumoto@ono-pharma.com


Public contact

Name of contact person

1st name Anri
Middle name
Last name Watanabe

Organization

3H Clinical Trial Co., Ltd.

Division name

Insight & Outcome Group

Zip code

171-0022

Address

1-13-23,Minamiikebukuro,Toshima-ku, Tokyo,JRE Minamiikebukuro Building 2F

TEL

03-5985-0053

Homepage URL


Email

a-watanabe@3h-ct.co.jp


Sponsor or person

Institute

Ono Pharmaceutical Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Ono Pharmaceutical Co., Ltd.
Bristol-Myers Squibb K.K.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Japan Conference of Clinical Research

Address

1-13-23,Minamiikebukuro,Toshima-ku, Tokyo.

Tel

03-6868-7022

Email

jccr-info@jccr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 12 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 12 Month 01 Day

Date of IRB

2022 Year 12 Month 16 Day

Anticipated trial start date

2022 Year 12 Month 23 Day

Last follow-up date

2023 Year 01 Month 16 Day

Date of closure to data entry

2023 Year 01 Month 16 Day

Date trial data considered complete

2023 Year 02 Month 01 Day

Date analysis concluded

2023 Year 07 Month 26 Day


Other

Other related information

None


Management information

Registered date

2022 Year 12 Month 21 Day

Last modified on

2023 Year 09 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056782


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name